Evidence map›Paper›PMID 26180219›Full record

ReviewNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2015

Are Pharmacotherapies Ineffective in Opioid-Dependent Smokers? Reflections on the Scientific Literature and Future Directions.

Mollie E Miller, Stacey C Sigmon

Open access · bronzeAbstract readReview
In one paragraph

Review in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Placebo-controlled trial of bupropion for smoking cessation in pregnant women.American journal of obstetrics & gynecology MFM · 2021
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Cigarette Smoking Cessation Intervention for Buprenorphine Treatment Patients.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2018
    Trial
  10. Trial
  11. The neuroimmune-glutamate hypothesis of addiction.Neuroscience and biobehavioral reviews · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Nicotine and Opioids: a Call for Co-treatment as the Standard of Care.The journal of behavioral health services & research · 2020
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Mollie E MillerCenter for Alcohol and Addictions Studies, Brown University, Providence, RI; mollie_patrick@brown.edu.
Stacey C SigmonVermont Center on Behavior and Health, University of Vermont, Burlington, VT; Department of Psychiatry, University of Vermont, Burlington, VT; Department of Psychology, University of Vermont, Burlington, VT.
Brown University · USUniversity of Vermont · US

Funding

Vermont Center on Behavior and HealthP20GM103644 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI HIGGINS, STEPHEN T · 2013 to 2022
$21.3M
Vermont Center on Tobacco Regulatory ScienceP50DA036114 · NIDA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI HIGGINS, STEPHEN T · 2013 to 2017
$19.1M
NIDA NIH HHS P50 DA036114NIGMS NIH HHS P20 GM103644
6 · The paper itself

Abstract

While rates of smoking in the general population have decreased in recent years, dramatic disparities remain among disadvantaged subgroups of smokers, particularly those with concurrent substance abuse. Prevalence rates of smoking among opioid-dependent patients, for example, are fourfold those of the general population. While pharmacotherapies are recommended as a first-line treatment for nicotine dependence, the few studies that have investigated their effectiveness in this population have shown dramatically poorer outcomes compared to the general population. Indeed, these findings have led some researchers to suggest that pharmacotherapies may simply be ineffective in opioid-maintained smokers. In this commentary, we briefly summarize the extant literature on pharmacotherapies in opioid-maintained smokers and contribute new data investigating the contribution of bupropion on smoking outcomes in 81 methadone- and buprenorphine-maintained participants from two randomized trials of financial incentives for smoking cessation. We also discuss several important parameters (ie, timing of the quit attempt, medication adherence, nicotine withdrawal) that may be leveraged to strengthen smoking pharmacotherapy outcomes in opioid-dependent patients. Taken together, an improved understanding of these issues will aid efforts to reduce tobacco-related health disparities in this group of challenging smokers.

Indexed as

Analgesics, OpioidBupropionForecastingHumansMethadoneOpioid-Related DisordersRandomized Controlled Trials as TopicSmokingSmoking CessationSubstance Withdrawal SyndromeTreatment OutcomeAnalgesics, OpioidBupropionMethadone

Identifiers

PMID26180219
PMCPMC4830239
OpenAlexW2398838534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.